A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis

Trial Profile

A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Intermediate uveitis; Panuveitis; Posterior uveitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms VISUAL III
  • Sponsors Abbott Healthcare; AbbVie
  • Most Recent Events

    • 12 Jul 2017 This trial was completed in Spain according to European Clinical Trials Database record.
    • 17 Jan 2017 Planned number of patients changed from 400 to 424.
    • 17 Jan 2017 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top